Zobrazeno 1 - 10
of 11
pro vyhledávání: '"John Spoors"'
Publikováno v:
The Journal of Haemophilia Practice. 9:50-63
Background The patient voice is an important consideration in the availability and choice of pharmaceuticals – however, how to capture this complex area and apply it formally within regulation, health technology assessment and reimbursement remains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61a96f4f65fde3bf57ac82856c600471
https://doi.org/10.2478/jhp-2022-0006
https://doi.org/10.2478/jhp-2022-0006
Autor:
Danny Palnoch, John Spoors, Joanne McEntee, Sheena Vithlani, John Cairns, Ash Summerfield, Alec Miners
Publikováno v:
BioDrugs. 35:1-5
Advanced therapy medicinal products (ATMPs) are a dynamic and current topic for healthcare systems, with new products progressing to market at an increasing rate. ATMPs highlight the growing gap between payer and regulator requirements; the limited e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c28ccb7c38798a0a2fc89431b1570ddf
https://doi.org/10.1007/s40259-020-00457-4
https://doi.org/10.1007/s40259-020-00457-4
Autor:
John, Spoors, Alec, Miners, John, Cairns, Danny, Palnoch, Ash, Summerfield, Joanne, McEntee, Sheena, Vithlani
Publikováno v:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 35(1)
Advanced therapy medicinal products (ATMPs) are a dynamic and current topic for healthcare systems, with new products progressing to market at an increasing rate. ATMPs highlight the growing gap between payer and regulator requirements; the limited e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1ebd1b32d46f85e145428b6e83b131db
https://pubmed.ncbi.nlm.nih.gov/33226582
https://pubmed.ncbi.nlm.nih.gov/33226582
Publikováno v:
British Journal of Healthcare Management. 23:158-166
Regenerative medicine is an emerging and pressing topic which represents an enigma for healthcare decision-makers around the globe. The ‘once and done’ concept is attractive not only to patients and clinicians, but also to payers in areas where t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45bd6cd2bd0294dab10c7268ef61dfea
https://doi.org/10.12968/bjhc.2017.23.4.158
https://doi.org/10.12968/bjhc.2017.23.4.158
Autor:
J. Kusel, John Spoors
Publikováno v:
British Journal of Healthcare Management. 22:267-277
The era of high-priced specialty pharmaceuticals is moving towards a pivotal moment. The cascade effect from the number of high-priced pharmaceuticals coming to market both now and in the future is causing payers to experience affordability challenge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8179d2f75113f2cbd41ad5e1aec59bf0
https://doi.org/10.12968/bjhc.2016.22.5.267
https://doi.org/10.12968/bjhc.2016.22.5.267
Autor:
John Spoors, Ischa J Es-Skali
Publikováno v:
Journal of comparative effectiveness research. 7(4)
Aim: To determine the preferred methodologies of health technology assessment (HTA) agencies across Europe, Canada and Australia to ascertain acceptance of indirect treatment comparisons (ITC) as a source of comparative evidence. Method: A review of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f15b495f77d35a42cf0a87f9691d59e7
https://pubmed.ncbi.nlm.nih.gov/29589475
https://pubmed.ncbi.nlm.nih.gov/29589475
Autor:
John Spoors, J. Kusel
Publikováno v:
British Journal of Healthcare Management. 21:331-342
With global healthcare budgets increasingly under pressure due to escalating costs, the spend on pharmaceuticals is a prime target for healthcare planners as it is the second largest budget item after staffing expenditure. Against this financial pres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a57a8b8614f051d300962c6296b2eab
https://doi.org/10.12968/bjhc.2015.21.7.331
https://doi.org/10.12968/bjhc.2015.21.7.331
Autor:
John Spoors, Emily Bennett
Publikováno v:
British Journal of Healthcare Management. 20:578-584
Since its inception over a decade ago, the National Institute for Health and Care Excellence (NICE) has evolved to become the central mechanism for determining value to the NHS for pharmaceutical products. Alternative mechanisms for funding products,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b111b8e6556725f6180151936ae247d
https://doi.org/10.12968/bjhc.2014.20.12.578
https://doi.org/10.12968/bjhc.2014.20.12.578
Autor:
John Spoors, Steve Bojakowski
Publikováno v:
British Journal of Healthcare Management. 20:384-391
The increasing number of patients suffering from rare diseases is creating greater demand for treatments. This, combined with an incentivised regulatory framework, is resulting in a significant number of novel but expensive treatments coming to marke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7991fe323add1d28b887c2ec347a9cb
https://doi.org/10.12968/bjhc.2014.20.8.384
https://doi.org/10.12968/bjhc.2014.20.8.384
Autor:
John Spoors
Publikováno v:
British Journal of Healthcare Management. 19:577-584
Pharmaceutical developments in oncology are moving at a considerable pace. This article provides an international perspective from both the USA and UK on the challenges payers are facing with regards to funding new oncology treatments. The article in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25326cecf49ec5f85d82b7fa056ce9eb
https://doi.org/10.12968/bjhc.2013.19.12.577
https://doi.org/10.12968/bjhc.2013.19.12.577